Abstract
The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
